Cells for Sight News Publication
- New research programme into Aniridia to go ahead at Moorfields Eye Hospital
- CFS will give five paper presentations and two posters at ARVO
- Hannah Levis awarded ARVO International Travel Grant
- UCLB patented technology used to develop a potential new treatment for Corneal Surface Disease
- Stefan Schrader successfully defends his PhD thesis
- Cells for Sight to host 5th Limbal Stem Cell Conference at UCL
- Hannah Levis appears in ESCRS Eurotimes
- Prof Julie Daniels invited speaker at the Gordon Conference in California
- Hannah Levis presents at the BCLA Evening Meeting
- New Postdoc joins the group
- Congrats to Marc for running the Paris Marathon!
- Julie Daniels interview on Insight Radio
- Eye disease cash for TAP Biosystems
- TAP, UCL Receive Additional Funding to Take Biomimetic Cornea into Human Safety Study
- New Scientific Data on use of Stem Cells for Ocular Surface Regeneration Presented by Daniels’ Group at Prestigious Ophthalmology Conference, ARVO
- ARVO 2012 report
- International Conference on Stem Cells and Regenerative Medicine
- Julie Daniels Fellow of the Society of Biology
- Welcome to Nuria Genicio!
- London 2012 Olympics is here!
- Farewell Marina!
- Welcome Sara Galindo!
- New research technician joins CFS
- 5th Limbal Stem Cell Meeting
- Recent Publications from CFS
- Alvena visits Prof. Funderburgh's lab in Pittsburgh
- Sarah and Alvena present at London Matrix Group
- Levis et al. manuscript accepted for publication in PLOS ONE
- Amanda Vernon successfully upgrades from MPhil to PhD
- We welcome a new member of CfS- Louise Morgan
- CfS do Movember!
- CfS Christmas Lunch
- New Endothelial RAFT article published in PLOS ONE available online now
- Aniridia Europe Meeting, Italy 2012
- CfS awarded UCL Beacon Bursary to host public engagement event
- Marc Dziasko successfully upgrades from MPhil to PhD
- Hannah and Victoria attend Aniridia Network UK Conference
- Alvena and Isobel visit Istanbul to attend TERMIS
- Marc attends the ISSCR annual conference
- Julie, Louise, Alex and Steve visit Japan
- Hannah and Marc present at the Vision of Excellence Congress in Berlin
- Cells for Sight team attend the 6th Limbal Stem Cell Forum in Liverpool
- Hannah has her paper published in Biomaterials
- Alex has his paper published in Stem Cells Translational Medicine
- Cornea Connect 2014
- Marc Dziasko has his paper published in PLoS ONE
- Hannah and Victoria raise £115 for Aniridia Network UK
- Cells for Sight team prepare for ARVO
- Julie receives PhD studentship funding from Fight for Sight
Eye disease cash for TAP Biosystems
29 April 2012
TAP Biosystems, which supplies cell culture systems and consumables for life science applications, has received further funding from the UK’s Technology Strategy Board.
The unspecified investment will advance the Cambridge UK company’s development of a biomimetic cornea to treat corneal surface disease, into pre-clinical research and a safety trial in two patients.
TAP will continue the collaboration with Professor Julie Daniels and her team at the Institute of Ophthalmology, University College London (UCL), developing the RAFT 3D tissue production technology to create high quality and consistent clinical grade tissues.
Professor Daniels, who began researching the clinical use of adult stem cells for repairing the human ocular surface over a decade ago, has been collaborating with TAP since 2008.
Her work has already shown that RAFT tissues, seeded with epithelial stem cells, can create corneal tissue which closely mimics the cells’ in vivo environment and supports stem cell growth, offering the potential to improve significantly on current success rates of ocular surface transplant surgery.
Professor Daniels said: “There is a genuine clinical problem with some biomaterials used to culture and transplant cells: The first generation material used in our transplant programme had a 40 per cent failure rate because the stem cells seeded on them do not always grow optimally.
“The RAFT process creates a natural collagen scaffold that can be engineered to replicate features of the stem cell niche and is a more realistic environment to support the stem cell population.
“The additional funding we have received from the Technology Strategy Board is a great vote of confidence in the potential of RAFT to deliver a corneal tissue equivalent, which we believe will be more effective in treating patients with blinding corneal surface damage.”
Dr Rosemary Drake, CSO at TAP Biosystems added: “Professor Daniels is one of the founding scientists in the application of stem cells for repair of the human ocular surface and we are delighted to have received the funding to continue developing the RAFT technology for her group to use in the clinical phase of their research.
“We look forward to seeing the results of the pre-clinical and clinical studies because they could provide the proof-of-concept that 3D tissues produced by the RAFT process have the potential to become novel regenerative therapies, which will enable more effective treatment of a range of debilitating conditions.”
Published 26th April 2012 in Business Weekly
Page last modified on 29 apr 12 18:28